S1PR1 and hypertensive disorder: Additionally, a study reported that the loss of endothelial S1PR1 expression in resistance arteries via fingolimod treatment, abolishes vasorelaxation, increases blood pressure in control mice, and exacerbates hypertension in the Ang-II mouse model (Cantalupo and Di Lorenzo, 2016).